The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Preclinical efficacy of the PKCβ inhibitor MS-553 in BTKi resistant CLL
In this video, Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, introduces the PKCβ inhibitor MS-553 and summarizes the currently available Phase I and preclinical data on this agent in patients with treatment-naïve chronic lymphocytic leukemia (CLL) and in patients who have relapsed after a BTK inhibitor. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
